Addition of sorafenib versus placebo to standard therapy in...

  • Main
  • 2015 / 11
  • Addition of sorafenib versus placebo to standard therapy in...

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Röllig, Christoph, Serve, Hubert, Hüttmann, Andreas, Noppeney, Richard, Müller-Tidow, Carsten, Krug, Utz, Baldus, Claudia D, Brandts, Christian H, Kunzmann, Volker, Einsele, Hermann, Krämer, Alwin, Sc
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(15)00362-9
Date:
November, 2015
File:
PDF, 373 KB
english, 2015
Conversion to is in progress
Conversion to is failed